<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Springerplus</journal-id><journal-id journal-id-type="iso-abbrev">Springerplus</journal-id><journal-title-group><journal-title>SpringerPlus</journal-title></journal-title-group><issn pub-type="epub">2193-1801</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24683527</article-id><article-id pub-id-type="pmc">3967734</article-id><article-id pub-id-type="publisher-id">776</article-id><article-id pub-id-type="doi">10.1186/2193-1801-2-668</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Activity of hypertonic solution with Silver and Potassium Sucrose Octasulfate on nasal symptoms in obstructive rhinopathy with and without rhinosinusitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Passali</surname><given-names>Desiderio</given-names></name><address><email>d.passali@virgilio.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Cambi</surname><given-names>Jacopo</given-names></name><address><email>ishajacopo@hotmail.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Passali</surname><given-names>Francesco Maria</given-names></name><address><email>passali@med.uniroma2.it</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Bellussi</surname><given-names>Luisa</given-names></name><address><email>l.bellussi@virgilio.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Dipartimento di Scienze neurologiche e sensoriali, Universit&#x000e0; di Siena, Viale Bracci, Siena, 11 53100 Italy </aff><aff id="Aff2"><label/>Dipartimento di Chirurgia, Universit&#x000e0; di Roma Tor Vergata, Viale Oxford 81, Roma, 00133 Italy </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="collection"><year>2013</year></pub-date><volume>2</volume><elocation-id>668</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; Passali et al.; licensee Springer. 2013</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Nasal obstruction is a primary symptom of common upper respiratory tract disorders. In clinical practice nasal saline solutions are recommended for the cleansing of nasal cavities and relieving nasal symptoms.</p></sec><sec><title>Methods</title><p>55 patients (aged 25&#x02013;70&#x000a0;years) suffering from obstructive rhinopathy, with nasal obstruction/congestion of moderate severity persistent since at least 10&#x000a0;days in advance of recruitment with/without rhinosinusitis was randomly treated with an hypertonic solution composed by Silver Sucrose Octasulfate and Potassium Sucrose Octasulfate (SILSOS) or isotonic solution for 20&#x000a0;days.</p><p>At baseline (T0), ten days (T10) and twenty days (T20) after SILSOS treatment, study participants were evaluated subjectively with VAS and SNOT-22, objectively by Active Anterior Rhinomanometry (AAR) and MCC/MCTt determination. Forty-four patients were followed-up 30&#x000a0;days after the end of treatment by a phone interview.</p></sec><sec><title>Results</title><p>The AAR analysis showed in SILSOS group a significantly (p&#x02009;&#x0003c;&#x02009;0.05) ameliorated in expiratory flow, at T0-T10 and T0-T20. No improvement in MCTt was observed over the 20&#x000a0;days study period. The mean values MCC of significantly improved at T20 (p&#x02009;&#x0003c;&#x02009;0.05). VAS total score showed improvement along all time-intervals. Nasal obstruction was back 30&#x000a0;days after the end of treatment with SILSOS in only 3 patients and reported to be in a mild form.</p></sec><sec><title>Conclusions</title><p>The obtained results show that SILSOS hyper has added to the mechanical action of removal of secretions a specific decongestant and antiseptic effect lasting longer after the end of treatment. Could help to fluidize thick mucus, improve respiration and promote resolution of symptoms, preventing pathogens adhesion to nasal mucosa.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nasal obstruction</kwd><kwd>VAS</kwd><kwd>SNOT-22</kwd><kwd>Rhinopathy</kwd><kwd>Silver sucrose octasulfate</kwd><kwd>Potassium sucrose octasulfate</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>The complaint of blockage, fullness, or restricted airflow are frequent in patients with nasal obstruction. The mucosal inflammation and decreased nasal patency, are common condition in cold and acute or chronic rhinosinusitis with/without nasal polyposis.</p><p>Rhinosinusitis are defined as inflammation of the nose and the paranasal sinuses characterized by two or more symptoms, one of which should be either nasal blockage obstruction congestion or nasal discharge (anterior/posterior nasal drip) &#x000b1; facial pain/pressure or &#x000b1; reduction or loss of smell (Fokkens et al. <xref ref-type="bibr" rid="CR9">2007</xref>; Rosenfeld et al. <xref ref-type="bibr" rid="CR25">2007</xref>; Scadding et al. <xref ref-type="bibr" rid="CR26">2008</xref>). Anterior Active Rhinomanometric (AAR) measurement of nasal resistance and nasal peak flow correlate well with subjective sensation of nasal obstruction (Fokkens et al. <xref ref-type="bibr" rid="CR8">2012</xref>; Passali et al. <xref ref-type="bibr" rid="CR22">2000</xref>), although this correlation remain uncertain (Andre et al. <xref ref-type="bibr" rid="CR1">2009</xref>). The AAR provides an objectively value of left, right, and total Nasal Airflow Resistance (NAR, NAR<sub>total</sub>&#x02009;= NAR<sub>left</sub> &#x000d7; NAR<sub>right</sub>/NAR<sub>left</sub> + NAR<sub>right</sub> (Clement <xref ref-type="bibr" rid="CR3">1991</xref>))<sub>.</sub></p><p>A 10-cm Visual Analogic Scale (VAS) was validated for patients with rhinosinusitis and divided the severity of disease into mild (VAS 0&#x02013;3), moderate (VAS &#x0003e;3-7) and severe (VAS &#x0003e;7-10) (Fokkens et al. <xref ref-type="bibr" rid="CR9">2007</xref>; Scadding et al. <xref ref-type="bibr" rid="CR26">2008</xref>; Fokkens et al. <xref ref-type="bibr" rid="CR8">2012</xref>). A VAS&#x02009;&#x0003e;&#x02009;5 affects patients Quality of Life (QOL) (Lim et al. <xref ref-type="bibr" rid="CR16">2007</xref>).</p><p>Sino-Nasal Outcome Tests (SNOT-22) (Hopkins et al. <xref ref-type="bibr" rid="CR12">2009</xref>) was an health related quality of life instrument for chronic rhinosinusitis and range from 0 (absence of symptoms) to 5 (the highest severity degree).</p><p>Mucociliary clearance (MCC) and/or the mucociliary transport time (MCTt) are involved in the defensive mechanisms against paranasal sinuses infection, in patients with rhinosinusitis assume pathological values due transudation that thickening the periciliary layer (Antunes et al. <xref ref-type="bibr" rid="CR2">2009</xref>; Cohen <xref ref-type="bibr" rid="CR4">2006</xref>; Passali <xref ref-type="bibr" rid="CR20">2003</xref>; Jones <xref ref-type="bibr" rid="CR13">2001</xref>).</p><p>MCC and MCTt were determined by means of the charcoal&#x02009;+&#x02009;3% saccharine test. The insoluble charcoal powder determinate the transport of foreign bodies like bacteria or dust particles entrapped into the outer mucus layer, the soluble saccharine measure the clearance (i.e. the dilution and drainage) of solutes into the inner mucus layer. The patient&#x02019;s perception of the sweet saccharine taste and the black color of charcoal in pharynx are easily detectable. MCC/MCTt is reported to take more than 30&#x000a0;minutes in pathological conditions; MCTt normal values are 13&#x02009;&#x000b1;&#x02009;2&#x000a0;minutes in adults; MCC normal values are 17&#x02009;&#x000b1;&#x02009;5&#x000a0;minutes in adults (Passali et al. <xref ref-type="bibr" rid="CR21">1984</xref>).</p><p>Endoscopic signs of rhinosinusitis are polyps and/or mucopurulent discharge primarily from middle meatus and/or oedema/mucosal obstruction primarily in middle meatus, that promote stasis of secretions and proliferation of bacteria to on sinonasal mucosa, bringing to an inflammatory mucosal response, worsening sinonasal symptoms and facilitating onset and/or recurrence of infections. Consequently, the solubilisation and release of secretions represent a basis of symptom resolution and functional improvement. Isotonic and hypertonic saline nasal wash/irrigation are an effective intervention, adjunct or not to medical therapy, to determinate MCC/MCTt recovery, reduce nasal mucosal edema, and make easy the elimination of microorganisms and secretions (Harvey et al. <xref ref-type="bibr" rid="CR10">2007</xref>; Thomas et al. <xref ref-type="bibr" rid="CR32">2008</xref>; S&#x000fc;sl&#x000fc; et al. <xref ref-type="bibr" rid="CR29">2009</xref>; Talbot et al. <xref ref-type="bibr" rid="CR31">1997</xref>).</p><p>In patients with acute upper respiratory tract infections saline nasal irrigation is associated with less time off work and with a tendency towards less antibiotic usage (Kassel et al. <xref ref-type="bibr" rid="CR15">2010</xref>).</p><p>SILSOS hyper, CM&#x00026;D Pharma Limited is a Medical Device (MD) composed by the association of Silver Sucrose Octasulfate (IASOS; US7183315, EP1458733) and Potassium Sucrose Octasulfate (KSOS). Combining the antimicrobial property of IASOS and the carbohydrate-based microbial antiadhesion of KSOS, SILSOS hyper restore nasal mucosae, reinforce the tropism through Fibroblast Growth Factor pathway activation and facilitate mucosal decongestion and hydration (Rashid et al. <xref ref-type="bibr" rid="CR23">1999</xref>; Yeh et al. <xref ref-type="bibr" rid="CR33">2002</xref>).</p><p>The main aim of this study was to valuated the efficacy of a 20&#x000a0;days period of treatment with MD on MCC and MCTt values compared to the simple treatment with isotonic solution. Valuate usefulness on primary and secondary symptoms of rhinosinusitis using visual analog scale (VAS) and Sino-Nasal Outcome Tests (SNOT-22) in patients with nasal respiratory obstruction.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>Between February 2012 and February 2013, 55 consecutive patients (aged 25&#x02013;70, 20 male) with obstructive rhinopathy of various aetiology were seen in our Department. Inclusion criteria was have persistent symptoms since at least 10&#x000a0;days in advance of recruitment due to inferior turbinate hypertrophy or congestion associated at a pre-existing deviated nasal septum, VAS&#x02009;&#x0003e;&#x02009;5 for two of the primary symptoms: nasal congestion, nasal obstruction and Rhinorrea or VAS&#x02009;&#x0003e;&#x02009;5 for one of the primary symptoms above and VAS &#x0003e;3 for at least one of the secondary symptoms: facial pain/pressure, reduction or loss of smell. Exclusion criteria were pregnancy, persistent/intermittent allergic rhinitis, cystic fibrosis, gross immunodeficiency (congenital or acquired), congenital mucociliary problems, fungal disease, systemic vasculitis and granulomatous diseases, cocaine abuse, diagnosis of nasal polyps (Lund/McKay II-III degree), nasal neoplasia; participation in other clinical trials within 3&#x000a0;months from enrolment; treatment with local and/or systemic corticosteroid, antibiotic, decongestants and nasal saline washes within one week from enrolment.</p><p>The patients were randomly assigned by a computer-generated eight blocks code to treatment by isotinic solution (n&#x02009;=&#x02009;30) or MD treatment (n&#x02009;=&#x02009;25).</p><p>Participants were evaluated subjectively with VAS and SNOT-22, and objectively with AAR, MCC and MCTt at baseline (T0), ten days (T10) and twenty days (T20) after MD treatment (2 sprays/nostril, two times a day for 20&#x000a0;days).</p><p>To assess compliance, the dispenser weight at T0 and at T20 were recorded.</p><p>All the patients were followed-up after 30&#x000a0;days the end of the treatment with a phone interview aimed to evaluate the long term effectiveness of the treatment.</p><p>After receiving detailed information about study aim, all participants signed their Informed Consent in compliance with the Declaration of Helsinki and current Good Clinical Practice. The study protocol was approved by the local Ethics Committee of the University Hospital &#x0201c;Le Scotte&#x0201d;, Siena (Nr 93/2011, November 22, 2011).</p><p>ANOVA was performed on continuous variables and categorical variables. Kruskal-Wallis were applied as appropriate for significance between treatment groups (Saline vs MD). Comparisons between groups were assessed by the Wilcoxon Signed Rank Test (significance of changes in secondary endpoints at different time intervals) or Friedman Test or <italic>t</italic>-test, as appropriate, at a significance level of p&#x02009;&#x0003c;&#x02009;0.05. Statistical analysis was performed with SPSS software (SPSS, Inc., Chicago, IL, USA).</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p>Twenty patients had acute rhinosinusitis at the beginning of the therapy with MD, these patients have associated at the nasal irrigation an antibiotic therapy (500&#x000a0;mg/die of fluoroquinolone drug class) for 14&#x000a0;days.</p><p>Controls of dispenser&#x02019;s weight does not have shown a lack of compliance by patients who have received treatment with MD while in 5 patients in the saline solution group there was a remaining weight more than 25% of the total at T1examination and therefore these patients were excluded from the study and from results.</p><p>AAR analysis were reported in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, at baseline total NAR were more than doubled the healthy 0,25&#x000a0;Pa/ml/s reported value (Clement <xref ref-type="bibr" rid="CR3">1991</xref>). MD progressively and significantly (p&#x02009;&#x0003c;&#x02009;0.05, Wilcoxon signed rank test) ameliorated in expiratory flow, both at T0-T10 and T0-T20. No significantly variation was observed in control group.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>AAR. Total nasal resistance at different timepoints</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">MD - Total resistance (Pa/ml/s)</th></tr><tr><th>Time</th><th align="left">Inspiratory flow</th><th align="left">Expiratory flow</th></tr></thead><tbody><tr><td>
<bold>T0</bold>
</td><td align="left">&#x02003;0.660&#x02009;&#x000b1;&#x02009;0.601</td><td align="left">&#x02002;&#x02009;0.662&#x02009;&#x000b1;&#x02009;0.579</td></tr><tr><td>
<bold>T10</bold>
</td><td align="left">&#x02003;0.510&#x02009;&#x000b1;&#x02009;0.427</td><td align="left">&#x02002;0.470&#x02009;&#x000b1;&#x02009;0.327*</td></tr><tr><td>
<bold>T20</bold>
</td><td align="left">&#x02003;0.420&#x02009;&#x000b1;&#x02009;0.218</td><td align="left">&#x02002;0.382&#x02009;&#x000b1;&#x02009;0.205*</td></tr></tbody></table><table-wrap-foot><p>*p&#x02009;&#x0003c;&#x02009;0.05 versus T0, Wilcoxon signed rank test.</p></table-wrap-foot></table-wrap></p><p>Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> report MCTt and MCC values at baseline, and after ten (T10) and twenty (T20) days of treatment. The mean value of MCTt at T0 was normal while MCC times were at the upper limits of the normal range. No significant improvement in MCTt was observed over the 20&#x000a0;day study period, or at T0-T10 and T10-T20 timepoints. The mean MCC values significantly improved at T20 (p&#x02009;=&#x02009;0.0003, Friedman test), the &#x00394;T0-T20 was 4.12&#x000a0;minutes. These differences have to be considered clinically significant. No significantly variation was observed in control group.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>MCTt and MCC at T0, T10 and T20 days after treatment. Data express the mean&#x02009;&#x000b1;&#x02009;SD</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>MCTt (minutes)</th><th>P (Friedman test)</th><th>MCC (minutes)</th><th>P (Friedman test)</th></tr></thead><tbody><tr><td rowspan="2">
<bold>T0</bold>
</td><td align="center" rowspan="2">13.0&#x02009;&#x000b1;&#x02009;1.10</td><td align="center">Vs T10&#x02009;&#x0003e;&#x02009;0.05</td><td align="center" rowspan="2">20.20&#x02009;&#x000b1;&#x02009;4.38</td><td align="center">Vs T10&#x02009;&#x0003e;&#x02009;0.05</td></tr><tr><td align="center">Vs T20&#x02009;&#x0003e;&#x02009;0.05</td><td align="center">Vs T20&#x02009;&#x0003c;&#x02009;0.05*</td></tr><tr><td>
<bold>T10</bold>
</td><td align="center">12.64&#x02009;&#x000b1;&#x02009;0.81</td><td align="center">Vs T20&#x02009;&#x0003e;&#x02009;0.05</td><td align="center">17.96&#x02009;&#x000b1;&#x02009;4.23</td><td align="center">Vs T20&#x02009;&#x0003e;&#x02009;0.05</td></tr><tr><td>
<bold>T20</bold>
</td><td align="center">12.72&#x02009;&#x000b1;&#x02009;0.84</td><td align="center">/</td><td align="center">16.08&#x02009;&#x000b1;&#x02009;4.24</td><td align="center">/</td></tr></tbody></table><table-wrap-foot><p>*p &#x0003c; 0.05 T0 versus T20, Friedman test.</p></table-wrap-foot></table-wrap></p><p>Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> reports VAS total score (mean&#x02009;&#x000b1;&#x02009;SD) for primary, primary plus secondary symptoms, and the VAS Mean Score (mean&#x02009;&#x000b1;&#x02009;SD), defined as: total symptoms score/n. symptoms, and expressing the severity of the reported symptoms. On the overall treatment period (T0-T20), MD improved VAS total score for primary, primary and secondary symptoms, and VAS mean score (p&#x02009;&#x0003c;&#x02009;0.05 vs T0). For primary and secondary symptoms MD showed a VAS total improvement along all time-intervals (p&#x02009;&#x0003c;&#x02009;0.05). In general, the MD demonstrated to be as effective on MCC times and better scores in primary, primary and secondary symptoms, and their severity degree at T0-T20. Similar variation in VAS total score (mean&#x02009;&#x000b1;&#x02009;SD) for primary, primary plus secondary symptoms, and the VAS Mean Score was reported at T20 in isotonic control group.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>VAS Total and Mean Score (mean&#x02009;&#x000b1;&#x02009;SD) at different timepoints in the two study groups</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Primary symptoms</th><th colspan="2">Primary&#x02009;+&#x02009;secondary symptoms</th><th colspan="2">Total score/n symptoms</th></tr><tr><th/><th colspan="2">VAS total score</th><th colspan="2">VAS total score</th><th colspan="2">VAS mean score</th></tr></thead><tbody><tr><td align="center"/><td align="center"/><td align="center">P (Friedman test)</td><td align="center"/><td align="center">P (Friedman test)</td><td align="center"/><td align="center">P (RM ANOVA)</td></tr><tr><td align="center" rowspan="2">
<bold>T0</bold>
</td><td align="center" rowspan="2">11,5&#x02009;&#x000b1;&#x02009;3,4</td><td align="center">Vs T10 &#x0003c; 0.05*</td><td align="center">15.6&#x02009;&#x000b1;&#x02009;3.7</td><td align="center">Vs T10 &#x0003c; 0.05*</td><td align="center">5,7&#x02009;&#x000b1;&#x02009;1,5</td><td align="center">Vs T10 &#x0003e; 0.05</td></tr><tr><td align="center">Vs T20 &#x0003c; 0.001**</td><td align="center"/><td align="center">Vs T20 &#x0003c; 0.001**</td><td align="center"/><td align="center">Vs T20 &#x0003c; 0.05&#x000b0;</td></tr><tr><td align="center">
<bold>T10</bold>
</td><td align="center">9,6&#x02009;&#x000b1;&#x02009;3,1</td><td align="center">Vs T20 &#x0003e; 0.05</td><td align="center">12.8&#x02009;&#x000b1;&#x02009;3.5</td><td align="center">Vs T20 &#x0003c; 0.05&#x000b0;&#x000b0;</td><td align="center">4,9&#x02009;&#x000b1;&#x02009;1,3</td><td align="center">Vs T20 &#x0003e; 0.05</td></tr><tr><td align="center">
<bold>T20</bold>
</td><td align="center">7,6&#x02009;&#x000b1;&#x02009;2,8</td><td align="center"/><td align="center">10.5&#x02009;&#x000b1;&#x02009;4.0</td><td align="center"/><td align="center">4,0&#x02009;&#x000b1;&#x02009;1,3</td><td align="center"/></tr></tbody></table><table-wrap-foot><p>*p &#x0003c; 0.05 T0 versus T10, Friedman test; **p &#x0003c; 0.001 T0 versus T20, Friedman test; &#x000b0;p &#x0003c; 0.05 T0 versus T20, Repeated Measures ANOVA; &#x000b0;&#x000b0;p &#x0003c; 0.05 T10 versus T20, Friedman test.</p></table-wrap-foot></table-wrap></p><p>Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> reported the effects of MD on the SNOT-22 scores, after twenty days of use an improvement in nasal obstruction/congestion, posterior nasal discharge and thick nasal discharge items was observed with an improvement in productivity and concentration items. In control group was detected an improvement in total SNOT-22 scores, in nasal obstruction/congestion item and in posterior nasal discharge.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Effect of the MD on the SNOT-22 Scores (Median values)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">&#x02003;&#x02003;&#x02003;&#x02003;&#x02003;ITEMS</th><th colspan="3">MD</th></tr><tr><th/><th>T0</th><th>T10</th><th>T20</th></tr></thead><tbody><tr><td>Need to blow the nose</td><td align="center">2,12&#x02009;&#x000b1;&#x02009;1,0 (2)</td><td align="center">2,28&#x02009;&#x000b1;&#x02009;1,0 (2)</td><td align="center">2,04&#x02009;&#x000b1;&#x02009;1,0 (2)</td></tr><tr><td>Sneezing</td><td align="center">1,40&#x02009;&#x000b1;&#x02009;1,2 (1)</td><td align="center">1,08&#x02009;&#x000b1;&#x02009;0,9 (1)</td><td align="center">0,88&#x02009;&#x000b1;&#x02009;0,9 (1)</td></tr><tr><td>Runny nose</td><td align="center">2,00&#x02009;&#x000b1;&#x02009;1,6 (2)</td><td align="center">2,00&#x02009;&#x000b1;&#x02009;1,5 (2)</td><td align="center">2,00&#x02009;&#x000b1;&#x02009;1,3 (2)</td></tr><tr><td>Cough</td><td align="center">0,76&#x02009;&#x000b1;&#x02009;1,0 (0)</td><td align="center">0,52&#x02009;&#x000b1;&#x02009;0,8 (0)</td><td align="center">0,44&#x02009;&#x000b1;&#x02009;0,9 (0)</td></tr><tr><td>Posterior nasal discharge</td><td align="center">1,68&#x02009;&#x000b1;&#x02009;1,5 (1)</td><td align="center">1,16&#x02009;&#x000b1;&#x02009;1,1 (1)</td><td align="center">0,60&#x02009;&#x000b1;&#x02009;0,8* (1)</td></tr><tr><td>Thick nasal discharge</td><td align="center">1,28&#x02009;&#x000b1;&#x02009;1,1 (1)</td><td align="center">0,72&#x02009;&#x000b1;&#x02009;0,7 (1)</td><td align="center">0,56&#x02009;&#x000b1;&#x02009;0,8* (1)</td></tr><tr><td>Ear fullness</td><td align="center">1,40&#x02009;&#x000b1;&#x02009;1,0 (1)</td><td align="center">1,20&#x02009;&#x000b1;&#x02009;0,7 (1)</td><td align="center">0,92&#x02009;&#x000b1;&#x02009;0,5* (1)</td></tr><tr><td>Dizziness</td><td align="center">------------</td><td align="center">------------</td><td align="center">------------</td></tr><tr><td>Ear pain</td><td align="center">0,12&#x02009;&#x000b1;&#x02009;0,4 (0)</td><td align="center">0,08&#x02009;&#x000b1;&#x02009;0,3 (0)</td><td align="center">0,00&#x02009;&#x000b1;&#x02009;0,0 (0)</td></tr><tr><td>Facial pain/pressure</td><td align="center">1,12&#x02009;&#x000b1;&#x02009;1,5 (1)</td><td align="center">0,84&#x02009;&#x000b1;&#x02009;1,3 (1)</td><td align="center">0,76&#x02009;&#x000b1;&#x02009;1,2 (1)</td></tr><tr><td>Difficulty falling asleep</td><td align="center">1,80&#x02009;&#x000b1;&#x02009;1,5 (2)</td><td align="center">1,60&#x02009;&#x000b1;&#x02009;1,3 (2)</td><td align="center">1,60&#x02009;&#x000b1;&#x02009;1,3 (2)</td></tr><tr><td>Waking up at night</td><td align="center">1,90&#x02009;&#x000b1;&#x02009;1,3 (2)</td><td align="center">1,40&#x02009;&#x000b1;&#x02009;1,2 (1)</td><td align="center">1,40&#x02009;&#x000b1;&#x02009;1,2 (1)</td></tr><tr><td>Lack of a good night sleep</td><td align="center">2,10&#x02009;&#x000b1;&#x02009;1,4 (2)</td><td align="center">1,60&#x02009;&#x000b1;&#x02009;1,3 (2)</td><td align="center">1,60&#x02009;&#x000b1;&#x02009;1,2 (2)</td></tr><tr><td>Waking up tired</td><td align="center">2,00&#x02009;&#x000b1;&#x02009;1,4 (2)</td><td align="center">1,80&#x02009;&#x000b1;&#x02009;1,1 (2)</td><td align="center">1,80&#x02009;&#x000b1;&#x02009;1,2 (2)</td></tr><tr><td>Fatigue</td><td align="center">1,90&#x02009;&#x000b1;&#x02009;1,4 (2)</td><td align="center">1,70&#x02009;&#x000b1;&#x02009;1,2 (2)</td><td align="center">1,40&#x02009;&#x000b1;&#x02009;1,3 (2)</td></tr><tr><td>Reduced productivity</td><td align="center">0,80&#x02009;&#x000b1;&#x02009;1,1 (1)</td><td align="center">0,64&#x02009;&#x000b1;&#x02009;1,1 (0)</td><td align="center">0,16&#x02009;&#x000b1;&#x02009;0,5**&#x000b0; (0)</td></tr><tr><td>Reduced concentration</td><td align="center">1,20&#x02009;&#x000b1;&#x02009;1,0 (1)</td><td align="center">0,64&#x02009;&#x000b1;&#x02009;1,0* (1)</td><td align="center">0,40&#x02009;&#x000b1;&#x02009;0,9** (0)</td></tr><tr><td>Frustrated/restless/irritable</td><td align="center">0,60&#x02009;&#x000b1;&#x02009;1,0 (0)</td><td align="center">0,36&#x02009;&#x000b1;&#x02009;0,9 (0)</td><td align="center">0,40&#x02009;&#x000b1;&#x02009;1,1 (0)</td></tr><tr><td>Sad</td><td align="center">0,04&#x02009;&#x000b1;&#x02009;0,2 (0)</td><td align="center">0,04&#x02009;&#x000b1;&#x02009;0,2 (0)</td><td align="center">0,12&#x02009;&#x000b1;&#x02009;0,6 (0)</td></tr><tr><td>Embarrassed</td><td align="center">0,04&#x02009;&#x000b1;&#x02009;0,2 (0)</td><td align="center">0,08&#x02009;&#x000b1;&#x02009;0,3 (0)</td><td align="center">0,12&#x02009;&#x000b1;&#x02009;0,6 (0)</td></tr><tr><td>Sense of smell/taste</td><td align="center">1,48 &#x000b1;1,6 (1)</td><td align="center">0,88&#x02009;&#x000b1;&#x02009;1,4 (1)</td><td align="center">0,68&#x02009;&#x000b1;&#x02009;1,2 (0)</td></tr><tr><td>Nasal obstruction/congestion</td><td align="center">4,64&#x02009;&#x000b1;&#x02009;0,5 (4)</td><td align="center">3,72&#x02009;&#x000b1;&#x02009;0,8** (3)</td><td align="center">2,96&#x02009;&#x000b1;&#x02009;0,9**<sup>&#x00394;</sup> (3)</td></tr><tr><td>TOTAL SCORE</td><td align="center">30,0&#x02009;&#x000b1;&#x02009;9,7 (28)</td><td align="center">24,2&#x02009;&#x000b1;&#x02009;8,4* (24)</td><td align="center">20,8&#x02009;&#x000b1;&#x02009;8,7** (21)</td></tr></tbody></table><table-wrap-foot><p>T20 Vs T0 : *p&#x02009;&#x0003c;&#x02009;0,05 **p&#x02009;&#x0003c;&#x02009;0.001; T20 Vs T10 : &#x000b0;p&#x02009;&#x0003c;&#x02009;0,05, <sup>&#x00394;</sup>p&#x02009;&#x0003c;&#x02009;0. 005 (Wilcoxon Test).</p></table-wrap-foot></table-wrap></p><p>MD effect on nasal obstruction/congestion and nasal discharge, being these symptoms of relevance in the clinical diagnosis of rhinosinusitis, were also considered in the small, good balanced subgroup of rhinosinusitis patients. Results are summarized in Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>SNOT-22, VAS Primary Simptoms and VAS Primary&#x02009;+&#x02009;Secondary Simptoms variation at T10 and T20.</bold> On the overall treatment period (T0-T20), MD improved VAS total score for primary, primary&#x02009;+&#x02009;secondary symptoms, and SNOT-22 mean score (p&#x02009;&#x0003c;&#x02009;0.05 vs T0).</p></caption><graphic xlink:href="40064_2013_776_Fig1_HTML" id="d30e1140"/></fig></p><p>All data about the control group was reported in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Control group data</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Isotonic solution</th><th>T0</th><th>T10</th><th>T20</th></tr></thead><tbody><tr><td>Inspiratory flow (Pa/ml/s)</td><td align="center">0.533&#x02009;&#x000b1;&#x02009;0.439</td><td align="center">0.507&#x02009;&#x000b1;&#x02009;0.336</td><td align="center">0.486&#x02009;&#x000b1;&#x02009;0.207</td></tr><tr><td>Expiratory flow (Pa/ml/s)</td><td align="center">0.542&#x02009;&#x000b1;&#x02009;0.435</td><td align="center">0.502&#x02009;&#x000b1;&#x02009;0.285</td><td align="center">0.475&#x02009;&#x000b1;&#x02009;0.212</td></tr><tr><td>MCTt (minutes)</td><td align="center">13.0&#x02009;&#x000b1;&#x02009;1.3</td><td align="center">12.88&#x02009;&#x000b1;&#x02009;0.78</td><td align="center">12.84&#x02009;&#x000b1;&#x02009;0.86</td></tr><tr><td>MCC (minutes)</td><td align="center">21.52 &#x000b1; 4.593</td><td align="center">19.68 &#x000b1; 4.498</td><td align="center">19.60 &#x000b1; 5.480</td></tr><tr><td>Primary symptoms</td><td align="center">11,2&#x02009;&#x000b1;&#x02009;3,7</td><td align="center">8,6&#x02009;&#x000b1;&#x02009;2,7*</td><td align="center">7,1&#x02009;&#x000b1;&#x02009;3,2**</td></tr><tr><td>Primary&#x02009;+&#x02009;secondary symptoms</td><td align="center">15.5&#x02009;&#x000b1;&#x02009;4.5</td><td align="center">12.4&#x02009;&#x000b1;&#x02009;4.0*</td><td align="center">10.5&#x02009;&#x000b1;&#x02009;4.1**</td></tr><tr><td>VAS Mean score</td><td align="center">5,6&#x02009;&#x000b1;&#x02009;1,7</td><td align="center">4,7&#x02009;&#x000b1;&#x02009;1,3</td><td align="center">4,0&#x02009;&#x000b1;&#x02009;1,5**</td></tr><tr><td>SNOT-22 Total score</td><td align="center">33,0&#x02009;&#x000b1;&#x02009;12,0</td><td align="center">26,0&#x02009;&#x000b1;&#x02009;10,0*</td><td align="center">22,0&#x02009;&#x000b1;&#x02009;11,0**</td></tr></tbody></table><table-wrap-foot><p>*T0 Vs T10&#x02009;&#x0003c;&#x02009;0.05 ; **T0 Vs T20&#x02009;&#x0003c;&#x02009;0.05.</p></table-wrap-foot></table-wrap></p><p>44/50 patients carried the follow up-interview, 30&#x000a0;days after treatment, only 3/22 patients of MD group reported the presence of subjective nasal obstruction, which was graded as a mild form. In control group 10/22 patients after 30&#x000a0;days reported the presence of subjective nasal obstruction.</p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>In our study population, nasal obstruction was the most relevant patients&#x02019; disorder as well as a major inclusion criteria to enrollment. After treatment, the more salient effect observed was the significantly decreased scoring for nasal obstruction/congestion on the overall treatment period. The symptom relief resulted to depend upon amelioration of posterior nasal discharge, thick discharge and ear fullness. These parameters suggest a success in fluidification of sinonasal secretions, supporting the recovery on health-related quality of life.</p><p>Although subjective assessment of nasal obstruction by patient-reported outcome measurements (PROMs) is a well-validated criterion, if little correlation were found between a patient-based symptom severity-scoring systems and an objective respiratory parameter, the impact of symptom amelioration could be overestimated. In our patients, a good matching of ameliorated PROMs and total nasal resistance was observed at T20, indicating an improved respiration.</p><p>Subjective improvement that was observed in the VAS scores and in SNOT 22 scores both in subjects treated with MD than in control group was not confirmed by the rhinometry data that showed an objective statistically significant improvement only in the MD group.</p><p>Rhinomanometry has been reported to correlate with subjective symptom scoring with and without decongestion (Eccles et al. <xref ref-type="bibr" rid="CR5">2005</xref>). There is an excellent correlation, considering studies with normal controls, patients with structural abnormalities, hyper-reactivity or infective rhinitis, between the subjective sensation of nasal obstruction and AAR values (Fairley et al. <xref ref-type="bibr" rid="CR7">1993</xref>; Sipil&#x000e4; et al. <xref ref-type="bibr" rid="CR28">1994</xref>; Simola and Malmberg <xref ref-type="bibr" rid="CR27">1997</xref>; Hirschberg and Rezek <xref ref-type="bibr" rid="CR11">1998</xref>; Numminen et al. <xref ref-type="bibr" rid="CR18">2003</xref>; Nathan et al. <xref ref-type="bibr" rid="CR17">2005</xref>). Even if some reports did not validate these data (Jones et al. <xref ref-type="bibr" rid="CR14">1989</xref>) or showed weak associations between PROMs and rhinomanometry (Eccles and Jones <xref ref-type="bibr" rid="CR6">1983</xref>; Roithmann et al. <xref ref-type="bibr" rid="CR24">1994</xref>; Panagou et al. <xref ref-type="bibr" rid="CR19">1998</xref>), does not necessarily imply that either subjective or objective scores are invalid, because these two approaches measure different aspects of the disease process. Subjective nasal obstruction correlates better with objective functional measurements of nasal airflow resistance (rhinomanometry, peak flow) than with measurements of nasal cavity width, such as acoustic rhinometry (Numminen et al. <xref ref-type="bibr" rid="CR18">2003</xref>; Sz&#x000fc;cs and Clement <xref ref-type="bibr" rid="CR30">1998</xref>). The measurement of nasal airway resistance by assessing nasal flow at a constant pressure can be useful in confirming that improvement in nasal congestion is the result of reduction in inflammation in the middle meatus rather than mechanical obstruction.</p><p>There is a limitation in main aim of the study because upon inclusion, patients had normal MCTt values and MCC times were at the upper limits of the normal range. Hence, no large improvements could be expected from a one to two week course of treatment. Considering these baseline values, the observed improvement in MCC can indeed be interpreted as clinically convincing. The greater success of the MD on the MCC times could depend on its hyper osmolarity. Hypertonic solutions are more helpful than isotonic solution since the drainage of the solutes into the inner &#x0201c;sol&#x0201d; layer can benefit of the dilution induced by the osmotic effect (Rashid et al. <xref ref-type="bibr" rid="CR23">1999</xref>). MCTt is expression of the equilibrium between both the inner &#x0201c;sol&#x0201d; layer and the outer &#x0201c;gel&#x0201d; layer and therefore, it needs prolonged or repeated treatments before a change could be appreciated.</p><p>An interesting findings comes from self-reported recurrences at follow-up. Nasal obstruction was back 30&#x000a0;days after the end of treatment in only 3 patients, and reported to be in a mild form. MD has the mechanical action of removal secretions, a specific decongestant and antiseptic effect lasting longer after the end of treatment.</p><p>MD could help to fluidize thick mucus, improve respiration and promote resolution of symptoms, in view of its natural decongestant activity and of its hydrating effects. MD were very well tolerated by patients since no adverse effect or complaints was recorded during the study, compliance was 78%.</p><p>The absence of Sodium Chloride in MD exclude the burning and bleeding events, sometime referred for nasal physiological solutions. The new MD seems to represent a secure alternative to present nasal salty preparations, alone or in adjunct to the medical therapy, with the advantage of a superior symptom relief.</p></sec><sec id="Sec5" sec-type="conclusions"><title>Conclusions</title><p>This paper describes the results obtained by patients with acute upper respiratory tract infections or obstructive rhinopathy from nasal irrigation with SILSOS hyper. At the mechanical action of removal secretions adds a specific decongestant and antiseptic effect lasting longer after the end of treatment which result in an improvement in PROMs like VAS and SNOT-22. Could help to fluidize thick mucus, improve respiration and promote resolution of symptoms, preventing pathogens adhesion to nasal mucosa.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>(AAR)</term><def><p>Anterior Active Rhinomanometric</p></def></def-item><def-item><term>(NAR)</term><def><p>Nasal Airflow Resistance</p></def></def-item><def-item><term>(VAS)</term><def><p>Visual Analogic Scale</p></def></def-item><def-item><term>(QOL)</term><def><p>Quality of Life</p></def></def-item><def-item><term>(SNOT-22)</term><def><p>Sino-Nasal Outcome Tests</p></def></def-item><def-item><term>(MCC)</term><def><p>Mucociliary Clearance</p></def></def-item><def-item><term>(MCTt)</term><def><p>Mucociliary Transport time</p></def></def-item><def-item><term>(MD)</term><def><p>Medical Device</p></def></def-item><def-item><term>(IASOS)</term><def><p>Silver Sucrose Octasulfate</p></def></def-item><def-item><term>(KSOS)</term><def><p>Potassium Sucrose Octasulfate</p></def></def-item><def-item><term>(PROMs)</term><def><p>Patient-Reported Outcome Measurements.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></fn><fn><p><bold>Authors' contributions</bold></p><p>DP, FMP, JC and LB were responsible for study conception and design. DP and FMP acquired the data. JC analysed the data. DP, JC and LB drafted the manuscript. DP is guarantor. All authors critically revised the manuscript and approved the final version.</p></fn></fn-group><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>RF</given-names></name><name><surname>Vuyk</surname><given-names>HD</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Graamans</surname><given-names>K</given-names></name><name><surname>Nolst Trenite</surname><given-names>GJ</given-names></name></person-group><article-title>Correlation between subjective and objective evaluation of the nasal airway. A systematic review of the highest level of evidence</article-title><source>Clin Otolaryngol</source><year>2009</year><volume>34</volume><fpage>518</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1111/j.1749-4486.2009.02042.x</pub-id><pub-id pub-id-type="pmid">20070760</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>MB</given-names></name><name><surname>Gudis</surname><given-names>DA</given-names></name><name><surname>Cohen</surname><given-names>NA</given-names></name></person-group><article-title>Epithelium, cilia, and mucus: their importance in chronic rhinosinusitis</article-title><source>Immunol Allergy Clin N Am</source><year>2009</year><volume>29</volume><fpage>631</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.iac.2009.07.004</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clement</surname><given-names>PAR</given-names></name></person-group><article-title>Rhinomanometry</article-title><source>Rhinology</source><year>1991</year><volume>14</volume><fpage>82</fpage></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>NA</given-names></name></person-group><article-title>Sinonasal mucociliary clearance in health and disease</article-title><source>Ann Otol Rhinol Laryngol Suppl</source><year>2006</year><volume>196</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">17040014</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eccles</surname><given-names>R</given-names></name><name><surname>Jawad</surname><given-names>MS</given-names></name><name><surname>Jawad</surname><given-names>SS</given-names></name><name><surname>Angello</surname><given-names>JT</given-names></name><name><surname>Druce</surname><given-names>HM</given-names></name></person-group><article-title>Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold</article-title><source>Am J Rhinol</source><year>2005</year><volume>19</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">15794071</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eccles</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>AS</given-names></name></person-group><article-title>The effect of menthol on nasal resistance to air flow</article-title><source>J Laryngol Otol</source><year>1983</year><volume>97</volume><fpage>705</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1017/S002221510009486X</pub-id><pub-id pub-id-type="pmid">6886530</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairley</surname><given-names>JW</given-names></name><name><surname>Durham</surname><given-names>LH</given-names></name><name><surname>Ell</surname><given-names>SR</given-names></name></person-group><article-title>Correlation of subjective sensation of nasal patency with nasal inspiratory peak flow rate</article-title><source>Clin Otolaryngol Allied Sci</source><year>1993</year><volume>18</volume><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2273.1993.tb00803.x</pub-id><pub-id pub-id-type="pmid">8448885</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokkens</surname><given-names>WJ</given-names></name><name><surname>Lund</surname><given-names>VJ</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Bachert</surname><given-names>C</given-names></name><name><surname>Alobid</surname><given-names>I</given-names></name><name><surname>Baroody</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Cervin</surname><given-names>A</given-names></name><name><surname>Douglas</surname><given-names>R</given-names></name><name><surname>Gevaert</surname><given-names>P</given-names></name><name><surname>Georgalas</surname><given-names>C</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name><name><surname>Harvey</surname><given-names>R</given-names></name><name><surname>Hellings</surname><given-names>P</given-names></name><name><surname>Hopkins</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Joos</surname><given-names>G</given-names></name><name><surname>Kalogjera</surname><given-names>L</given-names></name><name><surname>Kern</surname><given-names>B</given-names></name><name><surname>Kowalski</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Riechelmann</surname><given-names>H</given-names></name><name><surname>Schlosser</surname><given-names>R</given-names></name><name><surname>Senior</surname><given-names>B</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Toskala</surname><given-names>E</given-names></name><name><surname>Voegels</surname><given-names>R</given-names></name><name><surname>de Wang</surname><given-names>Y</given-names></name><name><surname>Wormald</surname><given-names>PJ</given-names></name></person-group><article-title>EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists</article-title><source>Rhinol</source><year>2012</year><volume>50</volume><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokkens</surname><given-names>WJ</given-names></name><name><surname>Lund</surname><given-names>VJ</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><collab>European Position Paper on Rhinosinusitis and Nasal Polyps group</collab></person-group><article-title>European position paper on rhinosinusitis and nasal polyps 2007</article-title><source>Rhinol Suppl</source><year>2007</year><volume>20</volume><fpage>1</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">17844873</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>R</given-names></name><name><surname>Hannan</surname><given-names>SA</given-names></name><name><surname>Badia</surname><given-names>L</given-names></name><name><surname>Scadding</surname><given-names>G</given-names></name></person-group><article-title>Nasal saline irrigations for the symptom of chronic rhinosinusitis</article-title><source>Cochrane Database Syst Rev</source><year>2007</year></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschberg</surname><given-names>A</given-names></name><name><surname>Rezek</surname><given-names>O</given-names></name></person-group><article-title>Correlation between objective and subjective assessments of nasal patency</article-title><source>ORL J Otorhinolaryngol Relat Spec</source><year>1998</year><volume>60</volume><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1159/000027595</pub-id><pub-id pub-id-type="pmid">9646308</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>C</given-names></name><name><surname>Gillett</surname><given-names>S</given-names></name><name><surname>Slack</surname><given-names>R</given-names></name><name><surname>Lund</surname><given-names>VJ</given-names></name><name><surname>Browne</surname><given-names>JP</given-names></name></person-group><article-title>Psychometric validity of the 22-item Sinonasal Outcome Test</article-title><source>Clin Otolaryngol</source><year>2009</year><volume>34</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/j.1749-4486.2009.01995.x</pub-id><pub-id pub-id-type="pmid">19793277</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>N</given-names></name></person-group><article-title>The nose and paranasal sinuses physiology and anatomy</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>51</volume><fpage>5</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00172-7</pub-id><pub-id pub-id-type="pmid">11516776</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>AS</given-names></name><name><surname>Willatt</surname><given-names>DJ</given-names></name><name><surname>Durham</surname><given-names>LM</given-names></name></person-group><article-title>Nasal airflow: resistance and sensation</article-title><source>J Laryngol Otol</source><year>1989</year><volume>103</volume><fpage>909</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1017/S0022215100110485</pub-id><pub-id pub-id-type="pmid">2584850</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kassel</surname><given-names>JC</given-names></name><name><surname>King</surname><given-names>D</given-names></name><name><surname>Spurling</surname><given-names>GK</given-names></name></person-group><article-title>Saline nasal irrigation for acute upper respiratory tract infections</article-title><source>Cochrane Database Syst Rev</source><year>2010</year></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Lew-Gor</surname><given-names>S</given-names></name><name><surname>Darby</surname><given-names>Y</given-names></name><name><surname>Brookes</surname><given-names>N</given-names></name><name><surname>Scadding</surname><given-names>G</given-names></name><name><surname>Lund</surname><given-names>VJ</given-names></name></person-group><article-title>The relationship between subjective assessment instruments in chronic rhinosinusitis</article-title><source>Rhinology</source><year>2007</year><volume>45</volume><fpage>144</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">17708462</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>RA</given-names></name><name><surname>Eccles</surname><given-names>R</given-names></name><name><surname>Howarth</surname><given-names>PH</given-names></name><name><surname>Steinsv&#x000e5;g</surname><given-names>SK</given-names></name><name><surname>Togias</surname><given-names>A</given-names></name></person-group><article-title>Objective monitoring of nasal patency and nasal physiology in rhinitis</article-title><source>J Allergy Clin Immunol</source><year>2005</year><volume>115</volume><fpage>S442</fpage><lpage>S459</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2004.12.015</pub-id><pub-id pub-id-type="pmid">15746882</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Numminen</surname><given-names>J</given-names></name><name><surname>Ahtinen</surname><given-names>M</given-names></name><name><surname>Huhtala</surname><given-names>H</given-names></name><name><surname>Rautiainen</surname><given-names>M</given-names></name></person-group><article-title>Comparison of rhinometric measurements methods in intranasal pathology</article-title><source>Rhinology</source><year>2003</year><volume>41</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">12868368</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagou</surname><given-names>P</given-names></name><name><surname>Loukides</surname><given-names>S</given-names></name><name><surname>Tsipra</surname><given-names>S</given-names></name><name><surname>Syrigou</surname><given-names>K</given-names></name><name><surname>Anastasakis</surname><given-names>C</given-names></name><name><surname>Kalogeropoulos</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of nasal patency: comparison of patient and clinician assessments with rhinomanometry</article-title><source>Acta Otolaryngol</source><year>1998</year><volume>118</volume><fpage>847</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1080/00016489850182567</pub-id><pub-id pub-id-type="pmid">9870632</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passali</surname><given-names>D</given-names></name></person-group><article-title>Inflammation in otorhinolaryngology</article-title><source>Acta Otorhinolaryngol Ital</source><year>2003</year><volume>23</volume><fpage>5</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15058602</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passali</surname><given-names>D</given-names></name><name><surname>Bellussi</surname><given-names>L</given-names></name><name><surname>Bianchini Ciampoli</surname><given-names>M</given-names></name><name><surname>De Seta</surname><given-names>E</given-names></name></person-group><article-title>Experiences in the determination of nasal mucociliary transport time</article-title><source>Acta Otolaryngol</source><year>1984</year><volume>97</volume><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.3109/00016488409130995</pub-id><pub-id pub-id-type="pmid">6539042</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passali</surname><given-names>D</given-names></name><name><surname>Mezzedimi</surname><given-names>C</given-names></name><name><surname>Passali</surname><given-names>GC</given-names></name><name><surname>Nuti</surname><given-names>D</given-names></name><name><surname>Bellussi</surname><given-names>L</given-names></name></person-group><article-title>The role of rhinomanometry, acoustic rhinometry, and mucociliary transport time in the assessment of nasal patency</article-title><source>Ear Nose Throat J</source><year>2000</year><volume>79</volume><fpage>397</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">10832207</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>MA</given-names></name><name><surname>Akita</surname><given-names>S</given-names></name><name><surname>Razzaque</surname><given-names>MS</given-names></name><name><surname>Yoshimoto</surname><given-names>H</given-names></name><name><surname>Ishihara</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name></person-group><article-title>Coadministration of basic fibroblast growth factor and sucrose octasulfate (sucralfate) facilitates the rat dorsal flap survival and viability</article-title><source>Plast Reconstr Surg</source><year>1999</year><volume>103</volume><fpage>941</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1097/00006534-199903000-00026</pub-id><pub-id pub-id-type="pmid">10077085</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roithmann</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>P</given-names></name><name><surname>Chapnik</surname><given-names>J</given-names></name><name><surname>Barreto</surname><given-names>SM</given-names></name><name><surname>Szalai</surname><given-names>JP</given-names></name><name><surname>Zamel</surname><given-names>N</given-names></name></person-group><article-title>Acoustic rhinometry, rhinomanometry, and the sensation of nasal patency: a correlative study</article-title><source>J Otolaryngol</source><year>1994</year><volume>23</volume><fpage>454</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">7897780</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>RM</given-names></name><name><surname>Andes</surname><given-names>D</given-names></name><name><surname>Bhattacharyya</surname><given-names>N</given-names></name><name><surname>Cheung</surname><given-names>D</given-names></name><name><surname>Eisenberg</surname><given-names>S</given-names></name><name><surname>Ganiats</surname><given-names>TG</given-names></name><name><surname>Gelzer</surname><given-names>A</given-names></name><name><surname>Hamilos</surname><given-names>D</given-names></name><name><surname>Haydon</surname><given-names>RC</given-names><suffix>3rd</suffix></name><name><surname>Hudgins</surname><given-names>PA</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Krouse</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>LH</given-names></name><name><surname>Mahoney</surname><given-names>MC</given-names></name><name><surname>Marple</surname><given-names>BF</given-names></name><name><surname>Mitchell</surname><given-names>CJ</given-names></name><name><surname>Nathan</surname><given-names>R</given-names></name><name><surname>Shiffman</surname><given-names>RN</given-names></name><name><surname>Smith</surname><given-names>TL</given-names></name><name><surname>Witsell</surname><given-names>DL</given-names></name></person-group><article-title>Clinical practice guideline: adult sinusitis</article-title><source>Otolaryngol Head Neck Surg</source><year>2007</year><volume>137</volume><fpage>S1</fpage><lpage>S31</lpage><pub-id pub-id-type="doi">10.1016/j.otohns.2007.06.726</pub-id><pub-id pub-id-type="pmid">17761281</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scadding</surname><given-names>GK</given-names></name><name><surname>Durham</surname><given-names>SR</given-names></name><name><surname>Mirakian</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>NS</given-names></name><name><surname>Drake-Lee</surname><given-names>AB</given-names></name><name><surname>Ryan</surname><given-names>D</given-names></name><name><surname>Dixon</surname><given-names>TA</given-names></name><name><surname>Huber</surname><given-names>PA</given-names></name><name><surname>Nasser</surname><given-names>SM</given-names></name><collab>British Society for Allergy and Clinical Immunology</collab></person-group><article-title>BSACI guidelines for the management of rhinosinusitis and nasal polyposis</article-title><source>Clin Exp Allergy</source><year>2008</year><volume>38</volume><fpage>260</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2222.2007.02889.x</pub-id><pub-id pub-id-type="pmid">18167126</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simola</surname><given-names>M</given-names></name><name><surname>Malmberg</surname><given-names>H</given-names></name></person-group><article-title>Sensation of nasal airflow compared with nasal airway resistance in patients with rhinitis</article-title><source>Clin Otolaryngol Allied Sci</source><year>1997</year><volume>22</volume><fpage>260</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2273.1997.00033.x</pub-id><pub-id pub-id-type="pmid">9222633</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sipil&#x000e4;</surname><given-names>J</given-names></name><name><surname>Suonp&#x000e4;&#x000e4;</surname><given-names>J</given-names></name><name><surname>Laippala</surname><given-names>P</given-names></name></person-group><article-title>Sensation of nasal obstruction compared to rhinomanometric results in patients referred for septoplasty</article-title><source>Rhinology</source><year>1994</year><volume>32</volume><fpage>141</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">7839086</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000fc;sl&#x000fc;</surname><given-names>N</given-names></name><name><surname>Bajin</surname><given-names>MD</given-names></name><name><surname>S&#x000fc;sl&#x000fc;</surname><given-names>AE</given-names></name><name><surname>O&#x0011f;retmeno&#x0011f;lu</surname><given-names>O</given-names></name></person-group><article-title>Effects of buffered 2.3%, buffered 0.9%, and non buffered 0.9% irrigation solutions on nasal mucosa after septoplasty</article-title><source>Eur Arch Otorhinolaryngol</source><year>2009</year><volume>266</volume><fpage>685</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1007/s00405-008-0807-5</pub-id><pub-id pub-id-type="pmid">18802718</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sz&#x000fc;cs</surname><given-names>E</given-names></name><name><surname>Clement</surname><given-names>PA</given-names></name></person-group><article-title>Acoustic rhinometry and rhinomanometry in the evaluation of nasal patency of patients with nasal septal deviation</article-title><source>Am J Rhinol</source><year>1998</year><volume>12</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.2500/105065898780182507</pub-id><pub-id pub-id-type="pmid">9805535</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>AR</given-names></name><name><surname>Herr</surname><given-names>TM</given-names></name><name><surname>Parsons</surname><given-names>DS</given-names></name></person-group><article-title>Mucociliary clearance and buffered hypertonic saline solution</article-title><source>Laryngoscope</source><year>1997</year><volume>107</volume><fpage>500</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1097/00005537-199704000-00013</pub-id><pub-id pub-id-type="pmid">9111380</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Yawn</surname><given-names>BP</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Lund</surname><given-names>V</given-names></name><name><surname>Mullol</surname><given-names>J</given-names></name><name><surname>Fokkens</surname><given-names>W</given-names></name><collab>European Position Paper on Rhinosinusitis and Nasal Polyps Group</collab></person-group><article-title>EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 - a summary</article-title><source>Prim Care Respir J</source><year>2008</year><volume>17</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.3132/pcrj.2008.00029</pub-id><pub-id pub-id-type="pmid">18438594</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>BK</given-names></name><name><surname>Eliseenkova</surname><given-names>AV</given-names></name><name><surname>Plotnikov</surname><given-names>AN</given-names></name><name><surname>Green</surname><given-names>D</given-names></name><name><surname>Pinnell</surname><given-names>J</given-names></name><name><surname>Polat</surname><given-names>T</given-names></name><name><surname>Gritli-Linde</surname><given-names>A</given-names></name><name><surname>Linhardt</surname><given-names>RJ</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name></person-group><article-title>Structural basis for activation of Fibroblast Growth Factor signaling by sucrose octasulfate</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>7184</fpage><lpage>7192</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.20.7184-7192.2002</pub-id><pub-id pub-id-type="pmid">12242295</pub-id></element-citation></ref></ref-list></back></article>